Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04263480
Title Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)
Acronym CZAR-1
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Christian Buske
Indications
Therapies
Age Groups: adult | senior
Covered Countries GRC | DEU | AUT


No variant requirements are available.